GlobeNewswire

ComInnex Inc. announces ISO 9001:2015 certification - Global chemistry service and research organization reinforces its commitment to deliver the highest quality services to the life science industry

Share

BUDAPEST, Hungary, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Today ComInnex, an innovator in the design and synthesis of novel compounds, DNA encoded library building blocks and provider of services for early stage drug discovery, announces that it has successfully obtained ISO 9001:2015 certification. The company previously earned certification under ISO 9001:2008, with the new accreditation underlining the commitment to maintain the highest standard in providing products and services to its global customer base.

We are very proud to earn this extended certification, which provides additional assurance to our customers that we are focused on continuous improvement and customer satisfaction,” said Chief Executive Officer, Alex Drijver.

By meeting the extensive criteria for these standards, ComInnex affirms its ability to consistently deliver effective quality management, comply with safety requirements, and drive continuous improvements involving products, services, governance and internal processes.

To obtain ISO 9001:2015 certification, an organization must demonstrate it practices evidence-based decision making, addresses risks and opportunities in a methodical manner, and ensures the quality policy and quality objectives are established for the quality management system, compatible with the context and strategic direction of the organization.

Our unique Open Collaboration on DNA Encoded Library Building Blocks brings together 9 major pharmaceutical companies; our FTE and Services team work intimately with customers on their projects. Such interactions require a high level of trust both in terms of confidentiality, as well as the quality of operations,” explained Alex Drijver. “Maintaining ISO 9001:2015 demonstrates our desire to always perform at the highest levels of quality and efficiency. It is essential to delivering innovative, high quality and customer-focused chemistry solutions to our partners.

About ComInnex
ComInnex is a chemistry service organization with strong interest and background in the development of chemical technologies. The company offers flexible business models, delivers a superior added value and provides the highest customer satisfaction and return on investment to all its partners. ComInnex strives to offer chemistry services and libraries unmatched by others, through a combination of proprietary technology, chemical know-how, with highest levels of quality and service.

For more information please contact Mr. Alexander Drijver, CEO: alex.drijver@cominnex.com

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Gilead and Galapagos Complete Closing of Their Transformative Research and Development Collaboration23.8.2019 22:01:00 CESTPress release

Foster City, Calif. and Mechelen, Belgium; 23 August 2019; 22.01 CET; regulated information – Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced the closing of the global research and development collaboration agreement signed on 14 July 2019. This agreement has received clearance from the U.S. Federal Trade Commission under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and merger control approval from the Austrian Federal Competition Authority. Under the terms of the agreement, the closing of this transaction triggers an upfront license fee payment of $3.95 billion by Gilead to Galapagos. In addition, Gilead has made an equity investment in Galapagos of approximately $1.1 billion (or approximately €960 million) by subscribing for new shares at a price of €140.59 per share, including issuance premium. As a result, Gilead now owns 13,589,686 ordinary shares of Galapagos, representing approximately 22 percent of the currently outsta

EVS Broadcast Equipment strikes major deal with NEP to upgrade their US production activities23.8.2019 18:00:00 CESTPress release

Publication on August 23 2019, 06:00 P.M. CET Regulated information – Privileged information EVS Broadcast Equipment S.A.: Euronext Brussels (EVS.BR), Bloomberg (EVS BB), Reuters (EVSB.BR) EVS STRIKES MAJOR DEAL WITH NEP TO UPGRADE THEIR US PRODUCTION ACTIVITIES EVS Broadcast Equipment, the leading provider of live production solutions, today announces that NEP is investing over $8m to deploy the next generation EVS live video production server as part of their US inventory. Liège, Belgium, August 23, 2019 EVS, the leading provider of live production solutions, has been selected by NEP, an international production company serving live broadcasting throughout the world, to deliver a major upgrade and upscale of their production facilities. The deal represents the acquisition of EVS’ XT-VIA next-generation live production servers, as well as the deployment of LSM replay controllers, IPDirector content management solutions and other infrastructure systems. All new systems will be installe

Clinical data on Idorsia's pipeline compounds will be presented at the European Society of Cardiology Congress 201923.8.2019 17:35:00 CESTPress release

Allschwil, Switzerland – August 23, 2019 Idorsia Ltd (SIX: IDIA) today announced that data from Phase 2 studies with aprocitentan, a new dual endothelin receptor antagonist, and selatogrel, a highly-selective P2Y12 receptor antagonist, will be shared during the European Society of Cardiology (ESC) Congress 2019 in Paris, France. Idorsia’s aprocitentan An oral presentation entitled "Efficacy and safety of various doses of the new dual endothelin receptor antagonist aprocitentan in the treatment of hypertension", will be part of the "Drug treatment in hypertension - New insights" session with a focused discussion with the lead author, Dr Parisa Danaietash from Idorsia, at 09:54 on August 31, 2019. The abstract can be found online. Idorsia’s selatogrel An oral presentation entitled "Selatogrel, a novel P2Y12 inhibitor for emergency use, achieves rapid, consistent and sustained platelet inhibition following single-dose subcutaneous administration in stable CAD patients", will be part of th

Millicom - H1 2019 Consolidated Financial Statements23.8.2019 16:53:00 CESTPress release

Millicom’s H1 2019 Consolidated Financial Statements Luxembourg, August 23, 2019— Millicom, a leading provider of cable and mobile services operating under the TIGO brand in Latin America, has published its H1 2019 consolidated financial statements. Contents include: • Management Report • Responsibility Statement • Review Report of the Independent Auditors • Unaudited Interim Condensed Consolidated Financial Statements -END- For further information, please contact Press: Vivian Kobeh, Corporate Communications Director +1 786-628-5300 press@millicom.com Investors: Michel Morin, VP Investor Relations +1 786-628-5270 investors@millicom.com Sarah Inmon, Investor Relations Manager +1-786-628-5303 investors@millicom.com About Millicom Millicom (NASDAQ U.S.: TIGO, Nasdaq Stockholm: TIGO_SDB) is a leading provider of cable and mobile services dedicated to emerging markets in Latin America and Africa. Millicom sets the pace when it comes to providing high-speed broadband and innovation around T

Conditions for Riksbank Bid Procedures Sek Bonds23.8.2019 16:20:00 CESTPress release

Sveriges Riksbank Bid procedure details Government Bonds, 2019-08-29 Maturity date Loan ISIN code Coupon Volume, SEK million 2025-05-12 1058 SE0005676608 2.50 % 500 +/- 250 2039-03-30 1053 SE0002829192 3.50 % 500 +/- 250 Settlement date 2019-09-02 Bids have to be entered by 10.00 on AUG 29, 2019 Highest permitted bid volume: 500 SEK million in issue SGB 1058 and 500 SEK million in issue SGB 1053 Lowest permitted bid volume: 50 SEK million Bids only through counterparties approved by the Riksbank RESULT OF AUCTION WILL BE PUBLISHED NO LATER THAN 10.10 (CEST) ON AUG 29, 2019. For more information, please contact: Trading desk at the Riksbank + 46 8 696 6970 General and special terms and conditions can be retrieved at http://www.riksbank.se